Last reviewed · How we verify

Infan Industria Quimica Farmaceutica Nacional — Portfolio Competitive Intelligence Brief

Infan Industria Quimica Farmaceutica Nacional pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Oral Aroeira Oral Aroeira phase 3 Serotonin receptor antagonist 5-HT2A receptor Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aclaris Therapeutics, Inc. · 1 shared drug class
  2. Addpharma Inc. · 1 shared drug class
  3. Appello Pharmaceuticals, Inc. · 1 shared drug class
  4. Gedeon Richter Plc. · 1 shared drug class
  5. Geropharm · 1 shared drug class
  6. H. Lundbeck A/S · 1 shared drug class
  7. Phytopharm Consulting Brazil · 1 shared drug class
  8. Shire · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Infan Industria Quimica Farmaceutica Nacional:

Cite this brief

Drug Landscape (2026). Infan Industria Quimica Farmaceutica Nacional — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/infan-industria-quimica-farmaceutica-nacional. Accessed 2026-05-18.

Related